> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lumateperone Tosylate NDA for Schizophrenia to Panel
- URL: https://www.fdaweb.com/lumateperone-tosylate-nda-for-schizophrenia-to-panel/
- Published: 2019-06-14T12:00:00.000Z
- Updated: 2026-09-15T01:32:44.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144341

*Federal Register* notice: FDA has announced a 7/31 Psychopharmacologic Drugs Advisory Committee meeting. Panel members are scheduled to discuss an Intra-Cellular Therapies NDA for lumateperone tosylate capsules, indicated for treating schizophrenia. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-06-14/pdf/2019-12558.pdf?ref=fdaweb.com).